Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2012 Jul 6

PMID 22762314

Citations 210

Authors

Matthew J Olnes

Phillip Scheinberg

Katherine R Calvo

Ronan Desmond

Yong Tang

Bogdan Dumitriu

Ankur R Parikh

Susan Soto

Angelique Biancotto

Xingmin Feng

Jay Lozier

Colin O Wu

Neal S Young

Cynthia E Dunbar

Affiliations

Soon will be listed here.

Abstract

Background: Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive therapy or allogeneic transplantation. One third of patients have disease that is refractory to immunosuppression, with persistent, severe cytopenia and a profound deficit in hematopoietic stem cells and progenitor cells. Thrombopoietin may increase the number of hematopoietic stem cells and progenitor cells.

Methods: We conducted a phase 2 study involving patients with aplastic anemia that was refractory to immunosuppression to determine whether the oral thrombopoietin mimetic eltrombopag (Promacta) can improve blood counts. Twenty-five patients received eltrombopag at a dose of 50 mg, which could be increased, as needed, to a maximum dose of 150 mg daily, for a total of 12 weeks. Primary end points were clinically significant changes in blood counts or transfusion independence. Patients with a response continued to receive eltrombopag.

Results: Eleven of 25 patients (44%) had a hematologic response in at least one lineage at 12 weeks, with minimal toxic effects. Nine patients no longer needed platelet transfusions (median increase in platelet count, 44,000 per cubic millimeter). Six patients had improved hemoglobin levels (median increase, 4.4 g per deciliter); 3 of them were previously dependent on red-cell transfusions and no longer needed transfusions. Nine patients had increased neutrophil counts (median increase, 1350 per cubic millimeter). Serial bone marrow biopsies showed normalization of trilineage hematopoiesis in patients who had a response, without increased fibrosis. Monitoring of immune function revealed no consistent changes.

Conclusions: Treatment with eltrombopag was associated with multilineage clinical responses in some patients with refractory severe aplastic anemia. (Funded by the National Heart, Lung, and Blood Institute; ClinicalTrials.gov number, NCT00922883.).

Citing Articles

Iron deficiency anemia following long-term eltrombopag treatment for aplastic anemia: a single-institution experience.

Yamamoto R, Hiramoto N, Nagai Y, Ishikawa T, Kondo T Int J Hematol. 2025; .

PMID: 39937332 DOI: 10.1007/s12185-025-03940-2.

Combining immunosuppressive therapy with low dosage eltrombopag in Chinese patients with severe aplastic anemia: mild aggravation of hepatic injury.

Chen X, Yu Q, Qin C, Zhang Y, Sun J, Jia J Ann Hematol. 2025; 104(1):155-162.

PMID: 39909905 PMC: 11868208. DOI: 10.1007/s00277-025-06210-7.

Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates.

da Fonseca A, da Fonseca A, Justino C, Campos de Molla V, Eiko Yamakawa P, Rabelo I Blood Adv. 2024; 9(4):906-912.

PMID: 39693508 PMC: 11876827. DOI: 10.1182/bloodadvances.2024014159.

The treatment and outcome prediction analysis of pediatric acquired severe aplastic anemia.

Li Y, Chen Y, Huang J, Chen X, Xue H, Cheng Y Am J Stem Cells. 2024; 13(5):233-242.

PMID: 39583757 PMC: 11578862. DOI: 10.62347/LACV8636.

Cyclosporine plus avatrombopag versus cyclosporine monotherapy for first-line treatment of elderly patients with transfusion-dependent non-severe aplastic anemia: a single center retrospective study.

Zhang Z, Hu Q, Wang L, Yang C, Chen M, Han B Ann Med. 2024; 56(1):2424451.

PMID: 39529509 PMC: 11559020. DOI: 10.1080/07853890.2024.2424451.

References

Calado R, Cooper J, Padilla-Nash H, Sloand E, Wu C, SCHEINBERG P . Short telomeres result in chromosomal instability in hematopoietic cells and precede malignant evolution in human aplastic anemia. Leukemia. 2011; 26(4):700-7. PMC: 4169071. DOI: 10.1038/leu.2011.272. View

Socie G, Mary J, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A . Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2006; 109(7):2794-6. DOI: 10.1182/blood-2006-07-034272. View

Kaushansky K . Historical review: megakaryopoiesis and thrombopoiesis. Blood. 2008; 111(3):981-6. PMC: 2214745. DOI: 10.1182/blood-2007-05-088500. View

Valdez J, Scheinberg P, Nunez O, Wu C, Young N, Walsh T . Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis. 2011; 52(6):726-35. PMC: 3106262. DOI: 10.1093/cid/ciq245. View

Scheinberg P, Cooper J, Sloand E, Wu C, Calado R, Young N . Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. JAMA. 2010; 304(12):1358-64. PMC: 3721502. DOI: 10.1001/jama.2010.1376. View

Erickson-Miller C, Delorme E, Tian S, Hopson C, Landis A, Valoret E . Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2008; 27(2):424-30. PMC: 2729672. DOI: 10.1634/stemcells.2008-0366. View

Rosenfeld S, Follmann D, Nunez O, Young N . Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003; 289(9):1130-5. DOI: 10.1001/jama.289.9.1130. View

Emmons R, Reid D, Cohen R, Meng G, Young N, Dunbar C . Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996; 87(10):4068-71. View

Gurion R, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I, Yeshurun M . Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis. Haematologica. 2009; 94(5):712-9. PMC: 2675684. DOI: 10.3324/haematol.2008.002170. View

10.

Kuter D . Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu Rev Med. 2009; 60:193-206. DOI: 10.1146/annurev.med.60.042307.181154. View

11.

Kuter D, Mufti G, Bain B, Hasserjian R, Davis W, Rutstein M . Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood. 2009; 114(18):3748-56. DOI: 10.1182/blood-2009-05-224766. View

12.

Viollier R, Passweg J, Gregor M, Favre G, Kuhne T, Nissen C . Quality-adjusted survival analysis shows differences in outcome after immunosuppression or bone marrow transplantation in aplastic anemia. Ann Hematol. 2004; 84(1):47-55. DOI: 10.1007/s00277-004-0930-3. View

13.

Qian H, Buza-Vidas N, Hyland C, Jensen C, Antonchuk J, Mansson R . Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2008; 1(6):671-84. DOI: 10.1016/j.stem.2007.10.008. View

14.

Zeigler F, De Sauvage F, Widmer H, Keller G, Donahue C, Schreiber R . In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells. Blood. 1994; 84(12):4045-52. View

15.

Manoharan A, Horsley R, Pitney W . The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol. 1979; 43(2):185-90. DOI: 10.1111/j.1365-2141.1979.tb03740.x. View

16.

Feng X, Scheinberg P, Wu C, Samsel L, Nunez O, Prince C . Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica. 2010; 96(4):602-6. PMC: 3069238. DOI: 10.3324/haematol.2010.030536. View

17.

Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A . Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano.... Br J Haematol. 1999; 107(2):330-4. DOI: 10.1046/j.1365-2141.1999.01693.x. View

18.

Kimura S, Roberts A, Metcalf D, Alexander W . Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A. 1998; 95(3):1195-200. PMC: 18717. DOI: 10.1073/pnas.95.3.1195. View

19.

Geddis A . Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer. 2011; 57(2):199-203. DOI: 10.1002/pbc.22927. View

20.

Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. DOI: 10.1016/0197-2456(89)90015-9. View